Combined intravitreal bevacizumab and argon laser treatment for Coats' disease.
Cackett
Peter
P
Wong
Doric
D
Cheung
Chui Ming Gemmy
CM
D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D005122:Exudates and Transudates; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D017075:Laser Coagulation; D054020:Lasers, Gas / Q000627:therapeutic use; D008297:Male; D012164:Retinal Diseases / Q000175:diagnosis / Q000628:therapy*; D012171:Retinal Vessels / Q000473:pathology*; D013684:Telangiectasis / Q000175:diagnosis / Q000628:therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab